Abstract
Acute pulmonary embolism is the third most common cause of cardiovascular death. Pulmonary embolism increases right ventricular afterload, which causes right ventricular failure, circulatory collapse and death. Most treatments focus on removal of the mechanical obstruction caused by the embolism, but pulmonary vasoconstriction is a significant contributor to the increased right ventricular afterload and is often left untreated. Pulmonary thromboembolism causes mechanical obstruction of the pulmonary vasculature coupled with a complex interaction between humoral factors from the activated platelets, endothelial effects, reflexes and hypoxia to cause pulmonary vasoconstriction that worsens right ventricular afterload. Vasoconstrictors include serotonin, thromboxane, prostaglandins and endothelins, counterbalanced by vasodilators such as nitric oxide and prostacyclins. Exogenous administration of pulmonary vasodilators in acute pulmonary embolism seems attractive but all come with a risk of systemic vasodilation or worsening of pulmonary ventilation-perfusion mismatch. In animal models of acute pulmonary embolism, modulators of the nitric oxide-cyclic guanosine monophosphate-protein kinase G pathway, endothelin pathway and prostaglandin pathway have been investigated. But only a small number of clinical case reports and prospective clinical trials exist. The aim of this review is to give an overview of the causes of pulmonary embolism-induced pulmonary vasoconstriction and of experimental and human investigations of pulmonary vasodilation in acute pulmonary embolism.

Keywords
right heart failure, pulmonary circulation, animal models, right ventricular afterload
This mismatch between thrombus mass and hemodynamic compromise raises the hypothesis that humoral responses and reflexes activated by the thrombus induce pulmonary vasoconstriction.

Key element in the treatment of PE is reduction of the thrombus mass. But this strategy only targets the mechanical component of the RV afterload increase. According to current guidelines, there are no recommended treatments targeting pulmonary vasoconstriction and its use is not reported in large registries, leaving a significant contributor to the adverse outcome in PE untreated.

Several experimental PE studies have shown a significant reduction in PVR using pulmonary vasodilators that targets a variety of pathways involved in pulmonary vascular tone. Despite evidence from pre-clinical studies, the clinical literature is dominated by case series and few small clinical trials using pulmonary vasodilators in PE.

We aim to provide a clinically relevant introduction to the mechanisms that induce pulmonary vasoconstriction in PE and a comprehensive review of both pre-clinical and clinical studies using pulmonary vasodilators in acute PE.

**Methods**

We searched MEDLINE via PubMed and Embase for relevant articles with latest update 13 September 2019 (see Appendix 1 for full search strategies).

Articles describing a medical intervention causing pulmonary vasodilation in acute PE using a clinically relevant drug were included. Both human and animal studies were included no matter the year of publication.

Exclusion criteria included especially studies on chronic thromboembolic pulmonary hypertension (CTEPH) and the other causes of pulmonary hypertension (PH) within the World Health Organization classification of PH. Please see Appendix 1 for full list of inclusion and exclusion criteria.

**Pulmonary vasoconstriction in acute PE**

Pulmonary vasoconstriction is a significant contributor to the increase of PVR in PE. This happens through a number of pathways which are not understood completely. The mechanisms are summarized in Fig. 1.

Hematogenous thromboembolism increases pulmonary arterial pressure (PAP) more effectively than...
non-hematogenous material, emphasizing the importance of PE-released vasoconstrictors. Evidence of these humoral or other chemicals was shown more than half a century ago. Activated platelets and the thrombus mass secrete thromboxane-A₂, prostaglandins, adenosine, thrombin, and serotonin which induce platelet aggregation and pulmonary vasoconstriction. Platelet-activating factor is also increased with acute PE. Pulmonary endothelial cells inactivate serotonin and certain prostaglandins to maintain homeostasis.

Endothelins (ET) are produced by the pulmonary vascular endothelium when stimulated by thrombin, endothelial injury and hypoxia. ET target the ETA and ETB receptors in the smooth muscle cells, and pulmonary vasoconstriction is induced by activation of phospholipase C that increases inositol triphosphate, diacylglycerol and intracellular calcium. ET have been estimated to be in charge of 25% of the PE-induced increase in PVR, but findings are variable. ET also induce bronchoconstriction and release of TXA₂ which further potentiate the pulmonary vasoconstrictor effect.

Prostaglandins cause either smooth muscle contraction or relaxation, depending on the prostaglandin subtype and receptor subtype. Smooth muscle contraction and subsequent vasoconstriction are mediated through receptor coupling with the phospholipase C pathway. In acute PE, elevated levels of prostaglandins that induce vasoconstriction have been observed, but prostaglandins may prevent the release of other vasoconstrictors. The clinical significance and the net pulmonary vasoconstrictor effect after vasodilation triggered by concomitant prostacyclin release are not known in acute PE.

Histamine release may also play a role in acute pulmonary embolism but have only been sparsely investigated making the clinical significance unknown. Hemolysis is present in PE causing a release of arginase which converts L-arginine to L-ornithine and urea. Otherwise, L-arginine would have had potential to produce L-citrulline and nitric oxide (NO) catalyzed by nitric oxide synthase. The consequence is reduced availability of NO as vasodilator. Additionally, released free heme and hemo-globin (Hb) reacts fast and irreversible with NO and further limits bioavailability of NO. This is normally counteracted by heme oxygenase-1 and by haptoglobin, but haptoglobin is decreased in PE patients. As NO causes pulmonary vasodilation, hemolysis can be an indirect cause of vasoconstriction. Hemolysis-released adenosine di-phosphate and free Hb enhance platelet activation which may cause further obstruction of the pulmonary vessels.

Furthermore, PE-induced vasoconstriction is augmented by local and neurogenic reflexes that might be dependent on localization of the PE. Sympathetic activity seems to be increased in both embolized and non-embolized parts of the lung. PE-released substances also cause bronchoconstriction of the small airways, leading to hypoxia and pulmonary vasoconstriction. Hypoxia in the lung tissue will inhibit synthesis of vasodilating prostanooids and worsen vasoconstriction.

For a summary, see Fig. 1. The different mechanisms of pulmonary vasoconstrictors in PE have been reviewed in details previously.

**Results**

Literature search resulted in 1510 papers and additional five were found by hand search. See Fig. 2 for flow chart on the screening process. A total of 92 papers were included in this review (summarized in Tables 1 to 4).

Here we provide a detailed review of experimental and clinical studies investigating the effects of pulmonary vasodilators in PE. For clarity of presentation, we divided these into four categories based on mechanism of action which will be presented first. The included articles will be presented with the experimental research followed by case reports and clinical studies. Tables 1 to 4 summarize the effects of pulmonary vasodilation in PE according to our review of the literature divided by pathway or mechanism.

**NO-sGC-cGMP pathway**

The nitric oxide (NO)-soluble guanulate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway exerts its pulmonary vasodilatory effects through paracrine interaction between the pulmonary endothelial cells (PEC) and the underlying smooth muscle cells (SMC). In the PEC, either shear stress or a humoral activator (e.g. serotonin, thrombin) causes increasing cytosolic levels of Ca²⁺ which activates the NO synthase. The active enzyme deaminates L-arginine to L-citrulline and NO. NO diffuses to the SMC where it activates sGC that dephosphorylates guanosine tri-phosphate (GTP) to cGMP which again activates cGMP-dependent protein kinase. Subsequently, sarcoplasmatic Ca²⁺-pumps are activated causing decreased cytosolic Ca²⁺ levels and decreased activation of calmodulin that otherwise is essential in the activation of myosin light-chain kinase and the myosin-actin cross-bridge cycle. As this is interrupted, the SMC relaxes and vasodilation occurs.

**Nitric oxide.** Inhaled NO (iNO) acts as a selective pulmonary agent. It has been suggested to have dual effects, i.e. pulmonary vasodilation through the above-mentioned mechanism in ventilated regions and pulmonary vasoconstriction through inhibition of endogenous NO synthase, most pronounced in hypoxic regions. Therefore, iNO can attenuate ventilation-perfusion mismatch and improve oxygenation. iNO can dilate the non-constricted pulmonary vasculature and works in combination with inhaled prostacyclin. NO protects (partly) from PE-induced pulmonary vasculature mRNA and the fraction of expiratory NO increases in
NO consumption increases in both animals and humans with PE, and the endogenous NO production seems lifesaving in PE as antagonism of NO synthase causes death in PE-animals. Accordingly, iNO has a potential therapeutic role in PE.

In general, iNO lowered PAP and PVR in animal models and increased cardiac output (CO) in some studies. The effect is possibly caused by reduced pulmonary vascular tone in the periphery of the pulmonary artery tree, especially regions with distally localized emboli. The reduced RV afterload might explain less myocardial damage evident by lowered cardiac troponins. One study using fat-emboli in a canine model did, however, not detect any effects on pulmonary or cardiac function.

Due to the rationale of inhaled administration, only one study noticed effect on the systemic vasculature with decreased mean arterial pressure (MAP). Some studies investigated dose–response relationship without consistent results, suggesting low-dose treatment to be favorable. iNO can be useful in combination with other treatment strategies where the agents showed additive effects on PAP, PVR or vessel diameter. The effects of iNO seem to be without prolonged effects.

Other NO-donors have also been tested in animal models of PE. Both nitroglycerin, nitrite and nitroprusside lower mean PAP and PVR but not always. One must be aware that systemic administration of NO-donors increases the risk of systemic side effects with decrease in MAP, systemic vascular resistance (SVR) or stroke volume, but not consistently. Combination of NO-donor and other vasodilators may be even more efficient but increases the risk of side effects.

NO has additional non-hemodynamic effects. iNO lowers von Willebrand factor and glycoprotein IIb/IIIa as central parts in endothelial function and thrombosis. NO affects apoptotic pneumocytes, and both endogenous and exogenous NO inhibits platelet aggregation in animals and humans which might be relevant in PE.
Table 1. Vasodilation through the NO-sGC-cGMP pathway in acute pulmonary embolism.

| Treatment | Experimental microsphere/glass beads/air PE | Experimental autologous (blood, fat, muscle, collagen) PE | Case reports | Clinical trials | Guideline recommendation |
|-----------|---------------------------------------------|-------------------------------------------------------------|--------------|----------------|-------------------------|
| Nitric oxide | Lowers PVR, mPAP but not MAP66,68–71,73,80,84–86 | Lowers PVR, mPAP increases CO 51,65,67,72,74–76,79,81–83 | 18 PE cases with mostly positive effects92–94,96,108 | Eight patients, single arm. Safe. Trend towards improvement112 | Either no recommendations16 or “Inhalation of nitric oxide may improve the hemodynamic status (…) no evidence for its clinical efficacy or safety”4 |
| sCG stimulators/activators | Lowers mPAP and PVR. Risk of decreased MAP84,118–120 | Lowers PVR and mPAP and increases CO75 | None | None | No recommendations4,16 |
| PDE-5 inhibitors | Lowers mPAP and PVR, no effect on MAP84,86,126–131 | Lowers mPAP and PVR 75,124,125 | Three PE cases136,138,139 | None | No recommendations4,16 |

Note: Summary of review of the NO-sGC-cGMP pathway to induce pulmonary vasodilation in acute pulmonary embolism. Divided by treatment option, animal or clinical data and guideline recommendation. Please see text for further details.

CO: cardiac output; iNO: inhaled nitric oxide; MAP: mean arterial pressure; mPAP: mean pulmonary arterial pressure; NO: nitric oxide; PAP: pulmonary artery pressure; PE: pulmonary embolism; PFO: persistent foramen ovale; PVR: pulmonary vascular resistance; SVR: systemic vascular resistance; VSD: ventricular septal defect.
NO has been used clinically in acute PE inspired by the experimental results and by the experience from using NO as a pulmonary vasodilator in acute respiratory distress syndrome and pulmonary hypertension.

A large variety of case reports have been published on the use of iNO, ranging from iNO administered to patients with RV failure (including PE-induced) as primary indication; as bridge to embolectomy or thrombolysis; with acute-on-chronic PE; during PE-induced cardiac arrest; on extra-corporal membrane oxygenation (ECMO) support or in case of contraindication to thrombolysis. Some cases describe the use of iNO to treat increased PAP after embolectomy of acute PE though not all with impressive hemodynamic responses. iNO has been used in children and even infants with PE without success. The influence of hemolysis on pulmonary vasoconstriction was evident in a case of autoimmune hemolytic anaemia, where PAP was significantly elevated despite only small clot burden, and iNO had impressive effect. iNO might also have negative effects. Case report data suggest that iNO-induced pulmonary vasodilation might worsen ventilation-perfusion mismatch and decrease oxygenation. Bhorade et al. only saw two of four PE patients with RV failure to respond to iNO. Tulleken et al. reported a case with a patient in cardiogenic shock due to PE and even low-dose iNO rapidly worsened PaO2 and saturation. The side effects disappeared when iNO was withdrawn. This patient may have had undiagnosed CTEPH, but the risk must be taken into consideration. Conversely, three of four patients reported by Capellier et al. presented with acute PE and a history of PE, and iNO showed positive effects in all cases.

A number of case reports describe significant or even dramatic positive hemodynamic effects of iNO, and the effects seem to be present shortly after beginning of treatment and at low doses. Whether these temporal improvements represent the direct effect of iNO remain uncertain.

A single arm, phase I study was followed by the phase II, iNOPE trial: a double-blinded, randomized,
multicenter trial where 76 patients with intermediate-high risk PE were randomized 1:1 to iNO (up to 50 ppm, delivered by nasal cannula) plus oxygen or nitrogen placebo at 50 ppm. The composite endpoint was complete normalization of troponins and RV function on echocardiogram after 24 h. The study was neutral on its primary and secondary endpoints but did show positive effects on RV hypokinesis and dilatation.111

For summary, please see Table 1.

**Soluble guanylate cyclase.** The dimeric enzyme, soluble guanylate cyclase (sGC) is activated by NO and catalyzes the second messenger cGMP from GTP. From a pharmacological perspective, the sCG enzyme has two oxidative states that determine its ability to produce cGMP. The constitutive, non-oxidized sGC enzyme contains a prosthetic heme moiety that binds NO and allows cGMP production, and can also increase cGMP production in the presence of specifically designed organic molecules known as “sGC stimulators”. For example, the sGC stimulator Riociguat is approved for the treatment of CTEPH but not acute PE. However, when exposed to oxidant stress, the sGC enzyme discharges the NO-binding the heme moiety and therefore cannot bind NO, but can be activated by an exosite with specifically designed organic molecules known as “sGC activators”. One commercially available activator is cinaciguat, which has been tested in humans with heart failure, but not in humans with PE. An important hypothetical consideration is that acute PE appears to produce an oxidative state in circulating platelets suggesting the possibility of pulmonary arterial endothelial sGC oxidation, which may impair effectiveness of iNO. PE-induced platelet hyperactivity (evident by increased cytosolic concentration of Ca2+) was not affected by iNO, but the Ca2+ concentration was suppressed by activation, but not stimulation, of sGC (unpublished data).

Regardless of its effect on sGC in the pulmonary vascular endothelial cells, stimulation of sGC also inactivates platelets and prolongs bleeding time which might be salutary in patients with PE.

A few animal studies have investigated the hemodynamic effects of sGC in PE, mostly in models of non-autologous PE material. The sGC stimulator BAY 41-8543 abolished the PE-induced hemodynamic changes, lowered blood lactate and PVR and increased CO. The stimulator BAY 41-2272 lowered PAP and PVR and even showed a dose–response relationship. However, the highest dose decreased MAP and SVR, too. In a porcine model of autologous PE, Riociguat lowered PVR in a dose-dependent manner and increased CO at high doses. See Table 1 for summary.

Our review did not find any clinical reports on the use of sGC-stimulation in PE in humans.

**Phosphodiesterase-5 inhibitors.** Cyclic guanosine monophosphate (cGMP) is the active second messenger in relaxation of SMC and pulmonary vasodilation. cGMP is inactivated by phosphodiesterase-5 (PDE-5). Inhibiting PDE-5 (e.g. with sildenafil) will increase the level of cGMP and cause pulmonary vasodilation. Inhibition of PDE-5 prevents...
Inhibition of the COX enzyme seems to improve hemodynamic changes in fat-embolism, suggesting the pathway also to be part of PE-pathophysiology. Non-specific PDE inhibition does reduce PAP and PVR without effects on MAP in PE.

In models of autologous PE, sildenafil improved hemodynamics in PE, though with a risk of decreased SVR. Sildenafil seems to prevent oxidative stress, nitric oxide consumption and pulmonary arterial endothelial apoptosis; effects that were enhanced by antioxidative N-acetylcysteine.

In a number of animal studies with microspheres, sildenafil has shown to lower mean PAP (mPAP) and PVR index, and in pigs with single lung ventilation-induced pulmonary hypertension, sildenafil dose-dependently enhanced desaturation. This effect may be species dependent, as sildenafil actually improves oxygenation in patients with pulmonary arterial hypertension.

Sildenafil has been used in PE in a few published case reports. Sildenafil showed promising effects in both acute post-operative PE and acute-in-chronic PE. In a patient with congenital heart disease and acute-in-chronic PE, sildenafil dramatically improved oxygenation. The use of sildenafil made withdrawal of inotropes possible shortly after treatment, whereas another case report measures the effects of sildenafil on the following day. This was, however, a severely ill patient with five-day history of saddle PE and in cardiogenic shock. The treatment may also be efficient in children.

Findings are summarized in Table 1.

**Prostanoid pathway**

Prostaglandins are products from arachidonic acid, catalyzed by cyclooxygenase (COX). They are mostly produced in endothelial cells and act at different receptors on the SMC with different downstream effects. Some receptors activate adenylate cyclase which dephosphorylates adenosine tri-phosphate to cyclic adenosine monophosphate that lowers cytosolic Ca\(^{2+}\) levels and causes pulmonary vasodilation. Other receptors inhibit the adenylate cyclase or activate phospholipase C, both to increase calcium levels and cause vasoconstriction which is why the net effect of increased prostanoid release in PE is complex.

Administration of the drugs can dilate pulmonary vasculature with both normal and constricted tone. Different prostanoids are secreted in acute PE. Inhibition of the COX enzyme seems to improve hemodynamics, suggesting prostaglandin synthesis to be central in the pathology of PE. PE may even cause release of negative inotropic agents, which is synthesized through the COX-pathway and might represent prostanoids. In one small randomized trial, administration of diclofenac was associated with a trend toward improved right ventricular function on echocardiography in humans with PE.

Besides hemodynamic effects, prostacyclin is one of the most potent endogenous inhibitors of platelet aggregation and may even enhance the effects of thrombolysis. Other prostanoids also prevent platelet aggregation, but platelets in acute thromboembolism may respond differently to prostanoids than normally. For example, on thromboelastography, platelets from patients with PE had a decreased response to adenosine diphosphate stimulation compared with platelets from healthy patients.

Preclinical studies have shown divergent hemodynamic effects with both prostacyclin (PGI2) and prostaglandin E1 (PGE1) with either no relevant response in dogs in both synthetic and autologous emboli material or a reduction in PVR or PAP. More consistently, in porcine models of non-autologous PE, both PGE1- and PGI2-administration reduce PVR and mPAP and even better than NO-donors, hydralazine and calcium channel blockers. In mice, both a PGI and PGE1 even reduced PE-related mortality, maybe through protective effects on the pulmonary vasculature in PE. The effects of PGI2 seem to have rapid onset, but duration of effects after cessation is more uncertain (see Table 2).

Risk of side effects must of course be kept in mind and should not exceed the benefits of treatment. Alpert et al. showed reduction in PAP in macro-embolism but not in micro-embolism when treated with PGE1, but in both situations noted a significant decrease in SVR and MAP. Similar reductions in MAP is noted both by PGE1 and PGI2.

Clinical case reports on the use of prostaglandins have been published. One case with CO2 gas emboli showed normalization of PAP only minutes after administration of inhaled epoprostenol. A total of seven cases with submassive PE showed positive effects of inhaled prostacyclin with a follow-up over weeks, whereas Webb et al. reported positive but transient effects on PAP without effects on MAP. This was in a PE patient that presented in shock and hence in a more critical condition. In one case of a newborn PE patient, epoprostenol showed no effect.

One clinical randomized, single-blinded trial has investigated the effects of prostaglandin treatment in acute PE. Kooter et al. randomized 14 PE patients to receive intravenous epoprostenol or placebo on top of standard treatment. Endpoints were echocardiographic and biochemical parameters. They did not find any significant effects of...
epoprostenol compared to placebo.\textsuperscript{163} The patients included by Kooter et al. had preserved tricuspid annular plane systolic excursion (TAPSE) and low right ventricular to left ventricular ratio at baseline and were perhaps not affected severely enough by their acute PE for epoprostenol to show an effect. The chosen prostaglandin or the route of administration may be another explanation to the lack of positive results as inhaled and intravenous prostaglandins have shown convincing effect in both CTEPH and primary pulmonary hypertension.\textsuperscript{164–166}

\textbf{Endothelin pathway}

ET (mostly ET-1) are produced in the lungs, especially the endothelium. Their synthesis is upregulated by shear stress, stretch, thrombin, hypoxia and pH but inhibited by NO and prostacyclin. ET exert paracrine effect on the SMC, bind to G-protein coupled ET\textsubscript{A} and ET\textsubscript{B} receptors which increases intracellular inositol triphosphate and calcium\textsuperscript{167} acting as potent vasoconstrictors and bronchoconstrictors.\textsuperscript{35,168} The effects of ET on the pulmonary vasculature might be complex, as it depends on the concentration of ET, the site of the receptor, the ongoing pathology and the tone of the pulmonary vasculature.\textsuperscript{85,168} ET also affect the release of NO and prostacyclin and play a role in the regulation of hypoxic pulmonary vasoconstriction\textsuperscript{35,167} which adds to the complexity. Whether or not ET concentrations are elevated in acute PE remains controversial.\textsuperscript{34,35}

Besides hemodynamic effects, ET stimulates platelet aggregation, cell adhesion and thrombosis,\textsuperscript{167} and plasma levels of ET are increased in both humans and in animal models during acute PE.\textsuperscript{169,170}

Antagonizing the ET receptors in acute PE has been investigated in a few animal studies (see Table 3). In dogs with autologous PE, ET-A antagonism lowered PAP and PVR and increased CO, also in combination with iNO.\textsuperscript{72,171,172} Han et al.\textsuperscript{171} even showed additive effects of combined ET-A antagonism and urokinase treatment. In air-embolism models, both non-selective ET-antagonist and ET-A antagonism lowered PAP and PVR,\textsuperscript{173,174} suggesting that the ET-A receptor to be responsible for most of ETs vasoconstrictive properties.\textsuperscript{85} In piglets, ET antagonism decreased PAP but lowered MAP and showed no effect on oxygenation or ventilation-perfusion mismatch.\textsuperscript{33,175} Conversely, in rodents with air-embolism, ET antagonism improved oxygenation and lowered RV systolic pressure.\textsuperscript{176,177}

Clinically, ET antagonism is widely used in CTEPH patients,\textsuperscript{178} but our review did not find any reports on the clinical use of ET antagonism in acute PE.

\textbf{Hydralazine}

Hydralazine dilates blood vessels, lowers blood pressure and is used in hypertension and congestive heart failure. Hydralazine opens Ca\textsuperscript{2+}-dependent potassium channels,\textsuperscript{179} causing hyperpolarization and closure of voltage-dependent Ca\textsuperscript{2+} channels which lowers cytosolic Ca\textsuperscript{2+} levels and causes relaxation. Mechanisms may also involve the inositol triphosphate pathway and the prostacyclin pathway.\textsuperscript{180,181} It appears that hydralazine can lower PVR in both normal and pathological conditions in animals and humans.\textsuperscript{182,183}

Hydralazine has been tested in experimental PE; please see Table 4 for a summary. In dogs with autologous PE, hydralazine lowered PVR and PAP and increased cardiac output,\textsuperscript{79,82,88,184} but a reduction in MAP was also noticed.\textsuperscript{79} One study did not see a reduction in PAP but positive effect on the output pressure.\textsuperscript{185} In a porcine model of glass bead-induced PE, hydralazine lowered MAP but was unable to lower mPAP and had the smallest reduction in PVR compared to PGE-1 and NO-donors. Hydralazine was, however, the only drug to increase cardiac output.\textsuperscript{80}

Besides the hemodynamic effects, hydralazine enhanced the effect of thrombolysis.\textsuperscript{184}

There are only few examples of the use of hydralazine in acute PE in humans. Bates et al. reported a case on a post-operative PE patient in shock. Hydralazine lowered PVR and PAP significantly over 24 h and increased cardiac index. After withdrawal of hydralazine, the hemodynamics deteriorated, and the treatment was repeated successfully.\textsuperscript{186} McGoon et al.\textsuperscript{187} reported 26 patients with pulmonary hypertension, of which 6 had PE as the underlying cause. In the PE-subgroup, hydralazine did not affect PVR nor PAP but increased pulmonary blood flow and arteriovenous oxygen difference and lowered SVR. The time frame of treatment was not reported relative to symptom onset (see Table 4).

We did not find any prospective, clinical study on the use of hydralazine in acute PE.

\textbf{Limitations}

This review contains some limitations to consider. Firstly, the broad diversity of animal models of PE makes it difficult to compare results directly between them. Species, emboli material and measurements and outcomes differ significantly among the included studies. Interpretation and translation must be done with caution. Secondly, the vast majority of the clinical publications are case reports with possible publication biases and accordingly, the level of evidence is low.

\textbf{Summary}

Several mechanisms of PE-induced pulmonary vasoconstriction are well described and represent potential therapeutic targets for pulmonary vasodilation in PE. Many of those were tested in animal models, which differ substantially in the choice of species and embolic material. Only a small number of case reports and clinical trials exist despite the treatment options have been available for decades.
Further research in pulmonary vasodilation as an adjunct to anticoagulation in acute PE is warranted but needs to be in pathophysiological relevant models and prospective clinical trials.

Authors' contribution
All authors participated in design and aim. MDL did the screening of papers and drafted the article. AA is the guarantor. All authors contributed substantially to and approved the final version of the article.

Conflict of interest
The author(s) declare that there is no conflict of interest.

Funding
MDL receives PhD scholarship from Aarhus University. The study was funded by the Novo Nordisk Foundation (NFF17CO0024868).

ORCID iD
Mads Dam Lyhne https://orcid.org/0000-0001-5279-260X

Supplemental material
Supplemental material for this article is available online.

References
1. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44: 62–69.
2. Cohen A, Agnelli G, Anderson F, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost 2007; 98: 756–764.
3. Greyson C, Xu Y, Lu L, et al. Right ventricular pressure and dilation during pressure overload determine dysfunction after pressure overload. Am J Physiol Heart Circ Physiol 2000; 278: H1414–20.
4. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2019; 39: 4208.
5. Wakefield TW, Myers DD and Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 2008; 28: 387–391.
6. Malik AB. Pulmonary microembolism. Physiol Rev 1983; 63: 1114–1207.
7. Kabrhel C, Okechukwu I, Harihara P, et al. Factors associated with clinical deterioration shortly after PE. Thorax 2014; 69: 835–842.
8. Kreit JW. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. CHEST 2004; 125: 1539–1545.
9. Ribeiro A, Lindmarker P, Juul H, et al. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997; 134: 479–487.
10. Goldhaber SZ, Visani L and De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386–1389.
11. Miller RL, Das S, Anandarangam T, et al. Association between right ventricular function and perfusion abnormalities in hemodynamically stable patients with acute pulmonary embolism. CHEST 1998; 113: 665–670.
12. McIntyre KM and Sasahara AA. Determinants of right ventricular function and hemodynamics after pulmonary embolism. Chest 1974; 65: 534–543.
13. Subramaniam RM, Mandrekar J, Chang C, et al. Pulmonary embolism outcome: a prospective evaluation of CT pulmonary angiographic clot burden score and ECG score. AJR Am J Roentgenol 2008; 190: 1599–1604.
14. Vedovati MC, Germini F, Agnelli G, et al. Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism: systematic review and meta-analysis. J Thromb Haemost 2013; 11: 2092–2102.
15. Meinel FG, Nance JW, Schoepf UJ, et al. Predictive value of computed tomography in acute pulmonary embolism: systematic review and meta-analysis. Am J Med 2015; 128: 747–59.
16. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: 1788–1830.
17. Jimenez D, de Miguel-Diez J, Guijarro R, et al. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE registry. J Am Coll Cardiol 2016; 67: 162–170.
18. Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000; 48: 23–33.
19. Stratmann G and Gregory AGA. Neurogenic and humoral vasoconstriction in acute pulmonary thromboembolism. Anesthesia & Analgesia 2003; 97: 341–354.
20. Halmagyi DF, Starzek J and Horner GJ. Humoral transmission of cardiorespiratory changes in experimental lung embolism. Circulation Research 1964; 14: 546–554.
21. Gurewich V, Cohen ML and Thomas DP. Pulmonary factors in massive pulmonary embolism: an experimental study. Am Heart J 1968; 76: 784–794.
22. Thomas DP, Gurewich V and Ashford TP. Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolism. N Engl J Med 1966; 274: 953–956.
23. Huval WV, Mathieson MA, Stemp L, et al. Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism. Ann Surg 1983; 197: 220–225.
24. Smith G and Smith AN. The role of serotonin in experimental pulmonary embolism. Surg Gynecol Obstet 1955; 101: 691–700.
25. Ueno Y, Kawashima A, Koike H, et al. Effect of beraprost sodium, a stable prostacyclin analogue, on pulmonary thromboembolism in mice. Thromb Res 1995; 77: 193–198.
26. Reeves WC, Demers LM, Wood MA, et al. The release of thromboxane A2 and prostacyclin following experimental acute pulmonary embolism. Prostaglandins Leuk Med 1983; 11: 1–10.
64. Agvald P, Adding LC, Nilsson KF, et al. Increased expired NO and roles of CO2 and endogenous NO after venous gas embolism in rabbits. Eur J Appl Physiol 2006; 97: 210–215.
65. Zhang Z, Pan K, Chen L, et al. The effect of nitric oxide inhalation on heart and pulmonary circulation in rabbits with acute massive pulmonary embolism. Exp Ther Med 2018; 16: 270–276.
66. Zwissler B, Welte M, Habler O, et al. Effects of inhaled pros-tacyclin as compared with inhaled nitric oxide in a canine model of pulmonary microembolism and oleic acid edema. J Cardiothorac Vasc Anesth 1995; 9: 634–640.
67. Nong Z, Hoylaerts M, Van Pelt N, et al. Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pul-monary thrombosis in rats. Circ Res 1997; 81: 865–869.
68. Gries A, Böttiger BW, Dörsam J, et al. Inhaled nitric oxide improves hemodynamics during a venous air infusion (VAI) in dogs. Intensive Care Med 1999; 25: 983–989.
69. Böttiger BW, Motsch J, Dörsam J, et al. Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary micro-embolism in piglets. CHEST 1996; 110: 1041–1047.
70. Tanus-Santos JE, Moreno H, Moreno RA, et al. Inhaled nitric oxide improves hemodynamics during a venous air infusion (VAI) in dogs. Anesth Analg 1999; 88: 1025–1029.
71. Lee J-H, Kim S, Park B-K, et al. The effect of a combination of inhaled nitric oxide and an endothelin A-receptor antagonist on hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Lung 2005; 183: 139–149.
72. Mélot C, Vermeulen F, Maggiorini M, et al. Site of pulmonary vasodilation by inhaled nitric oxide in microembolic lung injury. Am J Respir Crit Care Med 1997; 156: 75–85.
73. Döng C, Yang M, Lin Q, et al. Beneficial effects of inhaled NO inhibition of platelet aggregation and platelet-mediated pul-monary thrombosis in rats. Eur J Appl Physiol 2006; 97: 210–215.
74. Diaz-Junior CA, Montenegro MF, Florencio BC, et al. Small-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Basic Clin Pharmacol Toxicol 2008; 103: 374–379.
75. Noble WH and Kay JC. The effects of dobutamine, nitroprusside, or sildenafil in patients with pulmonary embolism. Am J Physiol 1988; 255: H1232–H1239.
76. Gries A, Herr A, Motsch J, et al. Randomized, placebo-con-trolled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers. Thromb Haemost 2000; 83: 309–315.
77. Shah J, Chastang C, Hamon M, et al. Inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999; 159: 571–579.
78. Schenck P, Mittermayer C and Ratheiser K. Inhaled nitric oxide in a patient with severe pulmonary embolism. Ann Emerg Med 1999; 33: 710–714.
79. Capellier G, Jaques T, Balvay P, et al. Inhaled nitric oxide in patients with pulmonary embolism. Intensive Care Med 1997; 23: 1089–1092.
80. McLean RF, Prielipp RC, Rosenthal MH, et al. Vasodilator therapy in microembolic porcine pulmonary hypertension. Anesth Analg 1990; 71: 35–41.
81. Yu D, Wang Y, Yu Y, et al. Acute beneficial effects of sodium nitroprusside in a rabbit model of massive pulmonary embolism associated with circulatory shock. Am J Pathol 2018; 188: 1768–1778.
82. Byrick RJ, Mollen DW, Slykerman L, et al. Effects of hydralazine and nitroprusside on cardiopulmonary function when a decrease in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
83. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
84. Overton ML, Das T, et al. Inhaled nitric oxide improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Rad Biol Med 2006; 41: 1764–1770.
85. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
86. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
87. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
88. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
89. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
90. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
91. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
92. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
93. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
94. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
95. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
96. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
97. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
98. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
99. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
100. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
101. Byrick RJ, Mullen JB, Murphy PM, et al. Inhaled nitric oxide reduces pulmonary vascular resistance and decreases in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68: 1299–1303.
97. Toolsie O, Gomceli U and Diaz-Fuentes G. Inhaled nitric oxide as an adjunct to thrombolytic therapy in a patient with submassive pulmonary embolism and severe hypoxemia. *Case Rep Crit Care* 2019; 5184702–5.

98. Sharma M, Suero-Abreu GA, Neupane R, et al. Role of phosphodiesterase-5 inhibitors in acute right ventricular failure due to pulmonary embolism. *Am J Case Rep* 2019; 20: 1144–1147.

99. Faintuch S, Lang EV, Cohen RI, et al. Inhaled nitric oxide as an adjunct to suction thrombectomy for pulmonary embolism. *J Vasc Intervent Radiol* 2004; 15: 1311–1315.

100. Trummer G, Berchtold-Herz M, Martin J, et al. Successful treatment of pulmonary hypertension with inhaled nitric oxide after pulmonary embolectomy. *Ann Thorac Surg* 2002; 73: 1299–1301.

101. Schenk P, Pernerstorfer T, Mittermayer C, et al. Inhalation of nitric oxide as a life-saving therapy in a patient after pulmonary embolectomy. *Br J Anaesth* 1999; 82: 444–447.

102. Spoehr F, Rehert GC, Böttiger BW, et al. Successful thrombolysis after pulmonary embolectomy for persistent massive postoperative pulmonary embolism. *Resuscitation* 2004; 62: 113–118.

103. Baird JS, Killinger JS, Kalkbrenner KJ, et al. Massive pulmonary embolism: a report of four patients and review of the literature. *Lung* 2006; 184: 1–5.

104. Summerfield DT, Desai H, Levitov A, et al. Inhaled nitric oxide as salvage therapy in massive pulmonary embolism: a case series. *Respir Care* 2012; 57: 444–448.

105. Lewis GD, Bloch KD and Semigran MJ. Pulmonary thromboembolism superimposed on a congenital ventricular septal defect in a 30-year-old man. *Cardiol Rev* 2004; 12: 188–190.

106. Tulleken JE, Zijlstra JG, Evers K, et al. Oxygen desaturation after treatment with inhaled nitric oxide for obstructive shock due to massive pulmonary embolism-to the editor. *CHEST* 1997; 112: 296–297.

107. Kline JA, Puskarich MA, Jones AE, et al. Inhaled nitric oxide to treat intermediate risk pulmonary embolism: a multicenter randomized controlled trial. *Nitric Oxide* 2019; 84: 60–68.

108. Kline JA, Hernandez J, Garrett JS, et al. Pilot study of a protocol to administer inhaled nitric oxide to treat severe acute submassive pulmonary embolism. *Emerg Med J* 2014; 31: 459–462.

109. Kline JA, Hall CL, Jones AE, et al. Randomized trial of inhaled nitric oxide to treat acute pulmonary embolism: The iNOPE trial. *Am Heart J* 2017; 186: 100–110.

110. Ghofrani H-A, Humbert M, Langleben D, et al. Riociguat: mode of action and clinical development in pulmonary hypertension. *CHEST* 2017; 151: 468–480.
131. Velásquez DRB, Teixeira-Neto FJ, Lagos-Carvajal AP, et al. Effects of different inspired oxygen fractions on sildenafil-induced pulmonary anti-hypertensive effects in a sheep model of acute pulmonary embolism. *Life Sci* 2015; 127: 26–31.

132. Kleinsasser A, Loockinger A, Hoermann C, et al. Sildenafil modulates hemodynamics and pulmonary gas exchange. *Am J Respir Crit Care Med* 2001; 163: 339–343.

133. Bonatti HJR, Sawyer RG and Hagspiel KD. Use of sildenafil in acute massive pulmonary vasculature during endovascular therapy – a case report. *Invest Surg* 2010; 42: 65–67.

134. Ganie re V, Feihl F and Tagan D. Dramatic beneficial effects of sildenafil in recurrent massive pulmonary embolism. *Intensive Care Med* 2006; 32: 452–454.

135. Hamilton-Craig CR, McNeil K, Dunning J, et al. Treatment options and strategies for acute severe pulmonary embolism. *Intern Med J* 2008; 38: 657–667.

136. Galea M and Quiney N. Sildenafil in acute pulmonary embolism: case report and review of literature. *J Intens Care Soc* 2009; 10: 44–45.

137. Bonatti HJR, Harris T, Bauer T, et al. Transfemoral catheter thrombolysis and use of sildenafil in acute massive pulmonary embolism. *J Cardiothorac Vase Anesth* 2010; 24: 980–984.

138. Naik SS, Sudhir V, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. *JAC* 2004; 44: 1488–1496.

139. Becker EM, Stasch J-P, Bechem M, et al. Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension. *PLoS ONE* 2013; 8: e73502.

140. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Hemodynamic and oxygenation profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. *Crit Care Med* 2001; 163: 339–343.

141. Jimenez D, Nieto R, Corres J, et al. Diclofenac for reversal of right ventricular dysfunction in acute normotensive pulmonary embolism: a pilot study. *Thromb Res* 2018; 162: 1–6.

142. Demling RH. Role of prostaglandins in acute pulmonary microvascular injury. *Ann N Y Acad Sci* 1982; 384: 517–534.

143. Coopera B. Diminished platelet adenylylate cyclase activation by prostaglandin D2 in acute thrombosis. *Blood* 1979; 54: 684–693.

144. Utsunomiya T, Kraus MM, Valeri CR, et al. Treatment of pulmonary embolism with prostacyclin. *Surgery* 1980; 88: 25–30.

145. Schneider J. Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of saruplase (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi. *Prostaglandins* 1991; 41: 595–606.

146. Alpert JS, Haynes FW, Dalen JE, et al. Experimental pulmonary embolism: effect on pulmonary blood volume and vascular compliance. *Circulation* 1974; 49: 152–157.

147. Utsunomiya T, Kraus MM, Shepro D, et al. Prostaglandin control of plasma and platelet 5-hydroxytryptamine in normal and embolized animals. *Am J Physiol* 1981; 241: H766–71.

148. Utsunomiya T, Kraus MM, Valeri CR, et al. Treatment of pulmonary embolism with positive end-expiratory pressure and prostaglandin E1. *Surg Gynecol Obstet* 1981; 153: 161–168.

149. Dervin G and Calvin JE. Role of prostaglandin E1 in reducing pulmonary vascular resistance in an experimental model of acute lung injury. *Crit Care Med* 1990; 18: 1129–1133.

150. Prielipp RC, MeLean R, Rosenthal MH, et al. Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. *Crit Care Med* 1991; 19: 60–67.

151. Hirose T, Aoki E, Ishibashi M, et al. The effect of prostacyclin on increased hydraulic conductivity of pulmonary exchange vessels following microembolization in dogs. *Microvasc Res* 1983; 26: 193–204.

152. Martineau A, Arcand GV, Couture P, et al. Transepophageal echocardiographic diagnosis of carbon dioxide embolism during minimally invasive saphenous vein harvesting and treatment with inhaled epoprostenol. *Anesth Analg* 2003; 96: 962–964.

153. Idrees MM, Batubara E and Kashour T. Novel approach for the management of sub-massive pulmonary embolism. *Ann Thorac Med* 2012; 7: 157–161.

154. Alsaghir AH, Alaitah SA, Alshahi B, et al. Iloprost in pulmonary hypertension due to sub-massive pulmonary embolism: report of two cases. *Libyan J Med* 2013; 8: 22391–22392.

155. Webb SAR, Stott S and van Heerden PV. The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism. *Intensive Care Med* 1996; 22: 353–355.

156. Kooter AJ, Ijzerman RG, Kamp O, et al. No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial. *BMC Pulm Med* 2010; 10: 18.

157. Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension*. *CHEST* 2003; 123: 338–343.
165. Krug S, Hammerschmidt S, Pankau H, et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 2008; 76: 154–159.

166. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. JACC 2000; 35: 176–182.

167. Lüscher TF and Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434–2440.

168. Sauvageau S, Thorin E, Caron A, et al. Endothelin-1-induced vasodilation in rabbit aorta and pulmonary artery. J Vas Res 2007; 44: 375–381.

169. Tsang J, Battistini B, Dussault P, et al. Biphase release of immunoreactive endothelins following acute pulmonary thromboembolism in pigs. J Cardiovasc Pharmacol 2000; 36: S221–S224.

170. Tanus-Santos JE, Gordo WM, Uedelmann A, et al. Endothelin abnormalities in patients with pulmonary embolism. CHEST 1997; 111: 544–549.

171. Han L, Li Q-Y, Zhou L, et al. Effects of thrombolytic drugs and a selective endothelin-1 receptor antagonist on acute pulmonary thromboembolism in dogs. Chin Med J 2010; 123: 395–400.

172. Lee JH, Chun YG, Lee IC, et al. Pathogenic role of endothelin 1 in hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Am J Respir Crit Care Med 2001; 164: 1282–1287.

173. Tanus-Santos JE, Gordo WM, Uedelmann A, et al. Nonselective endothelin-receptor antagonism attenuates hemodynamic changes after massive pulmonary air embolism in dogs. CHEST 2000; 118: 175–179.

174. Tsang JYC, Lamm WJE, Neradilek B, et al. Endothelin receptor blockade does not improve hypoxemia following acute pulmonary thromboembolism. J Appl Physiol 2007; 102: 762–771.

175. Ayach B, Tsang J, Jeng AY, et al. Effects of a selective endothelin A receptor antagonist, ABT-627, in healthy normotensive anaesthetized rats developing acute pulmonary air embolism. Clin Sci 2002; 103(Suppl 48): 371S–375S.

176. Battistini B, Verrecalt M, Ayach B, et al. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model. J Cardiovasc Pharmacol 2004; 1(44 Suppl 1): S386–S9.

177. Becattini C, Manina G, Busti C, et al. Bosentan for chronic thromboembolic pulmonary hypertension: Findings from a systematic review and meta-analysis. Thromb Res 2010; 126: e51–e56.

178. Bang L, Nielsen-Kudsk JE, Gruhn N, et al. Hydralazine-induced vasodilation involves opening of high conductance Ca2-activated K channels. Eur J Pharmacol 1998; 361: 43–49.

179. Ellershaw DC and Gurney AM. Mechanisms of hydralazine-induced vasodilation in rabbit aorta and pulmonary artery. Br J Pharmacol 2001; 134: 621–631.

180. Maille N, Gokina N, Mandalà M, et al. Mechanism of hydralazine-induced relaxation in resistance arteries during pregnancy: hydralazine induces vasodilation via a prostacyclin pathway. Vasc Pharmacol 2016; 78: 36–42.

181. Lupi-Herrera E, Furuya ME, Sandoval J, et al. Effect of hydralazine on vascular mechanics in a canine lobar preparation of pulmonary embolism. Lung 1992; 170: 291–309.

182. Rubin LJ and Peter RH. Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med 1980; 302: 69–73.

183. Prewitt RM, Downes AMT, Gu S, et al. Effects of hydralazine and increased cardiac output on recombintant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism*. CHEST 1991; 99: 708–714.

184. Ducas J, Girling L, Schick U, et al. Pulmonary vascular effects of hydralazine in a canine preparation of pulmonary thromboembolism. Circulation 1986; 73: 1050–1057.

185. Bates ER, Crevey BJ, Sprague FR, et al. Oral hydralazine therapy for acute pulmonary embolism and low output state. Arch Intern Med 1981; 141: 1537–1538.

186. Meesoom V, Sutcliffe PJ, Chang PY, et al. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension. Br Heart J 1983; 50: 579–585.

Appendix 1. Search strategy

We searched MEDLINE via PubMed and Embase for relevant articles with latest update September 13th 2019. We used the following search strategies for PubMed: (acute pulmonary embolism OR “Pulmonary Embolism”[Mesh]) AND (“Vasodilation”[Mesh] OR “Vasodilator Agents”[Mesh] OR “Hydralazine”[Mesh] OR “Phosphodiesterase Inhibitors”[Mesh] OR “Sildenafil”[Mesh] OR “Soluble Guanylyl Cyclase”[Mesh] OR “Guanylate Cyclase”[Mesh] OR “riociguat”[Supplementary Concept] OR “Endothelin Receptor Antagonists”[Mesh] OR “Nitric Oxide”[Mesh] OR “Nitroprusside”[Mesh] OR “Nitroglycerin”[Mesh] OR “Prostaglandins”[Mesh] OR “Epoprostenol”[Mesh] OR “Hydralazine” OR endothelin receptor antagonist OR bosentan OR tezosentan OR macitentan OR prostacyclin OR epoprostenol OR prostaglandins OR sildenafil OR tadalafil OR phosphodiesterase-5 inhibitor OR riociguat OR soluble guanylyl cyclase OR inhaled nitric oxide) and for Embase: (“hydralazine”/exp OR “phosphodiesterase inhibitor”/exp OR “sildenafil”/exp OR “tadalafil”/exp OR “riociguat”/exp OR “guanylate cyclase”/exp OR “endothelin receptor antagonist”/exp OR “boventan”/exp OR “tezosentan”/exp OR “macitentan”/exp OR “nitric oxide”/exp OR “inhaled nitric oxide”/exp OR “nitroprusside sodium”/exp OR “glyceryl trinitrate”/exp OR “prostacyclin”/exp OR “prostacyclin derivate”/exp OR “i-loprost”/exp OR “prostaglandin h2”/exp OR “prostaglandin e2”/exp OR “prostacyclin e1”/exp OR “prostacyclin derivate”/exp AND (“acute pulmonary embolism”/exp OR “lung embolism”/exp) AND (“article”/it OR “article in press”/it).
Titles and abstracts were screened for relevance by MDL. If eligible, the article was read and deemed for inclusion or not. References were reviewed for further hits.

Articles were included if they described a medical intervention causing pulmonary vasodilation in acute PE including air embolism using a clinically relevant drug. No specific needs for comparison were required (either control group or repeated measurements). Any hemodynamic outcome was accepted. Both human and animal studies were included no matter the year of publication. Only English papers were included.

Exclusion criteria included studies on chronic thromboembolic pulmonary hypertension (CTEPH) and the other causes of pulmonary hypertension (PH) within the World Health Organization classification of PH; studies that investigated causes in PE-induced pulmonary vasoconstriction but did not intervene; and animal models that did not have an actual embolism (toxins or pharmacologically induced acute PH, e.g. by a thromboxane analog), and studies on isolated perfused lungs. We did not include studies on inodilators in this review. Case reports without sufficient description of hemodynamic effects of the vasodilatory agent were excluded. We excluded abstracts, conference papers, comments, editorials, and reviews.

Due to the broad variety of PE-models and outcome measures, no specific synthesis of outcome or meta-analysis was possible. We sum up hemodynamic findings in Tables 1 to 4.